Literature DB >> 26524591

Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production.

Anja Brehm, Yin Liu, Afzal Sheikh, Bernadette Marrero, Ebun Omoyinmi, Qing Zhou, Gina Montealegre, Angelique Biancotto, Adam Reinhardt, Adriana Almeida de Jesus, Martin Pelletier, Wanxia L Tsai, Elaine F Remmers, Lela Kardava, Suvimol Hill, Hanna Kim, Helen J Lachmann, Andre Megarbane, Jae Jin Chae, Jilian Brady, Rhina D Castillo, Diane Brown, Angel Vera Casano, Ling Gao, Dawn Chapelle, Yan Huang, Deborah Stone, Yongqing Chen, Franziska Sotzny, Chyi-Chia Richard Lee, Daniel L Kastner, Antonio Torrelo, Abraham Zlotogorski, Susan Moir, Massimo Gadina, Phil McCoy, Robert Wesley, Kristina I Rother, Kristina Rother, Peter W Hildebrand, Paul Brogan, Elke Krüger, Ivona Aksentijevich, Raphaela Goldbach-Mansky.   

Abstract

Autosomal recessive mutations in proteasome subunit β 8 (PSMB8), which encodes the inducible proteasome subunit β5i, cause the immune-dysregulatory disease chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), which is classified as a proteasome-associated autoinflammatory syndrome (PRAAS). Here, we identified 8 mutations in 4 proteasome genes, PSMA3 (encodes α7), PSMB4 (encodes β7), PSMB9 (encodes β1i), and proteasome maturation protein (POMP), that have not been previously associated with disease and 1 mutation in PSMB8 that has not been previously reported. One patient was compound heterozygous for PSMB4 mutations, 6 patients from 4 families were heterozygous for a missense mutation in 1 inducible proteasome subunit and a mutation in a constitutive proteasome subunit, and 1 patient was heterozygous for a POMP mutation, thus establishing a digenic and autosomal dominant inheritance pattern of PRAAS. Function evaluation revealed that these mutations variably affect transcription, protein expression, protein folding, proteasome assembly, and, ultimately, proteasome activity. Moreover, defects in proteasome formation and function were recapitulated by siRNA-mediated knockdown of the respective subunits in primary fibroblasts from healthy individuals. Patient-isolated hematopoietic and nonhematopoietic cells exhibited a strong IFN gene-expression signature, irrespective of genotype. Additionally, chemical proteasome inhibition or progressive depletion of proteasome subunit gene transcription with siRNA induced transcription of type I IFN genes in healthy control cells. Our results provide further insight into CANDLE genetics and link global proteasome dysfunction to increased type I IFN production.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26524591      PMCID: PMC4639987          DOI: 10.1172/JCI81260

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12.

Authors:  S Matikainen; A Paananen; M Miettinen; M Kurimoto; T Timonen; I Julkunen; T Sareneva
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

2.  The structure of the mammalian 20S proteasome at 2.75 A resolution.

Authors:  Masaki Unno; Tsunehiro Mizushima; Yukio Morimoto; Yoshikazu Tomisugi; Keiji Tanaka; Noritake Yasuoka; Tomitake Tsukihara
Journal:  Structure       Date:  2002-05       Impact factor: 5.006

3.  An unknown autoinflammatory syndrome associated with short stature and dysmorphic features in a young boy.

Authors:  André Mégarbané; Agnès Sanders; Eliane Chouery; Valérie Delague; Myrna Medlej-Hashim; Paul-Henri Torbey
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

4.  Salt wasting and deafness resulting from mutations in two chloride channels.

Authors:  Karl P Schlingmann; Martin Konrad; Nikola Jeck; Petra Waldegger; Stephan C Reinalter; Martin Holder; Hannsjörg W Seyberth; Siegfried Waldegger
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

5.  A deletion involving the connexin 30 gene in nonsyndromic hearing impairment.

Authors:  Ignacio del Castillo; Manuela Villamar; Miguel A Moreno-Pelayo; Francisco J del Castillo; Araceli Alvarez; Dolores Tellería; Ibis Menéndez; Felipe Moreno
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

Review 6.  Inflammatory responses in influenza A virus infection.

Authors:  I Julkunen; K Melén; M Nyqvist; J Pirhonen; T Sareneva; S Matikainen
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

7.  Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder.

Authors:  N Katsanis; S J Ansley; J L Badano; E R Eichers; R A Lewis; B E Hoskins; P J Scambler; W S Davidson; P L Beales; J R Lupski
Journal:  Science       Date:  2001-09-21       Impact factor: 47.728

8.  IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells.

Authors:  Elisabetta Padovan; Giulio C Spagnoli; Maria Ferrantini; Michael Heberer
Journal:  J Leukoc Biol       Date:  2002-04       Impact factor: 4.962

Review 9.  Central role of defective apoptosis in autoimmunity.

Authors:  W M Kühtreiber; T Hayashi; E A Dale; D L Faustman
Journal:  J Mol Endocrinol       Date:  2003-12       Impact factor: 5.098

Review 10.  Dysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases.

Authors:  Anja Brehm; Elke Krüger
Journal:  Semin Immunopathol       Date:  2015-05-12       Impact factor: 11.759

View more
  89 in total

1.  CANDLE Syndrome: orodfacial manifestations and dental implications.

Authors:  T Roberts; L Stephen; C Scott; T di Pasquale; A Naser-Eldin; M Chetty; S Shaik; L Lewandowski; P Beighton
Journal:  Head Face Med       Date:  2015-12-28       Impact factor: 2.151

Review 2.  Genetically defined autoinflammatory diseases.

Authors:  A A de Jesus; R Goldbach-Mansky
Journal:  Oral Dis       Date:  2016-04-14       Impact factor: 3.511

Review 3.  Genomics, Biology, and Human Illness: Advances in the Monogenic Autoinflammatory Diseases.

Authors:  Hirotsugu Oda; Daniel L Kastner
Journal:  Rheum Dis Clin North Am       Date:  2017-08       Impact factor: 2.670

4.  The Caenorhabditis elegans RIG-I Homolog DRH-1 Mediates the Intracellular Pathogen Response upon Viral Infection.

Authors:  Jessica N Sowa; Hongbing Jiang; Lakshmi Somasundaram; Eillen Tecle; Guorong Xu; David Wang; Emily R Troemel
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

Review 5.  Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.

Authors:  Zhong-Xun Yu; Hong-Mei Song
Journal:  World J Pediatr       Date:  2019-08-03       Impact factor: 2.764

Review 6.  [Clinical aspects and genetics of proteasome-associated autoinflammatory syndromes (PRAAS)].

Authors:  E Feist; A Brehm; T Kallinich; E Krüger
Journal:  Z Rheumatol       Date:  2017-05       Impact factor: 1.372

Review 7.  An Update on Autoinflammatory Diseases: Interferonopathies.

Authors:  Sophia Davidson; Annemarie Steiner; Cassandra R Harapas; Seth L Masters
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

8.  Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4.

Authors:  Adriana A de Jesus; Anja Brehm; Rachel VanTries; Pascal Pillet; Anne-Sophie Parentelli; Gina A Montealegre Sanchez; Zuoming Deng; Isabelle Koné Paut; Raphaela Goldbach-Mansky; Elke Krüger
Journal:  J Allergy Clin Immunol       Date:  2019-01-18       Impact factor: 10.793

Review 9.  The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation.

Authors:  Kalpana Manthiram; Qing Zhou; Ivona Aksentijevich; Daniel L Kastner
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

Review 10.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.